Sign Out
1) Mosapride Citrate (GASTIIN CR) should not be used in pregnant women, women who may possibly be pregnant, only if the expected therapeutic benefits outweigh the possible risks associated with the treatment. (Safety in pregnant women has not been established.)
2) Administration of Mosapride Citrate (GASTIIN CR) to nursing mothers should be avoided. If administration is essential, nursing mothers should discontinue breastfeeding during the treatment. (Animal (rat) experiments have shown that Mosapride citrate is excreted in breast milk.)
Continue with Google